Skip to content

Welcome to Discover Pharma! Today is : October 28, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

rhinovirus

  • Clinical & Regulatory,Pharmaceuticals and therapeutics,Research & Development,Therapeutic Areas

    ENA Respiratory begins Phase 2a dosing of nasal antiviral INNA-051

    ENA Respiratory has begun dosing participants in Part B of [...]

    September 15, 2026
  • Advanced Therapies,Drug Discovery & Development,Opinion & Events

    Ethris begins Phase 2a trial of intranasal mRNA candidate ETH47 for virus-triggered asthma

    Ethris has dosed the first patient in a Phase 2a [...]

    May 5, 2026

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Johnson & Johnson reports three-year Crohn’s disease results for guselkumab
    Categories: Clinical & Regulatory, Pharmaceuticals and therapeutics, Therapeutic Areas
  • Ryvu reports preclinical results for novel ADC payload
    Categories: Drug Discovery & Development, Research & Development
  • Kindeva wins $226 million contract for nerve agent antidote autoinjectors
    Categories: Manufacturing & Supply Chain
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details.
OK
Go to Top